tert-butyl N-[2-[2-[3-(9H-fluoren-9-ylmethoxycarbonylamino)propanoylamino]ethyldisulfanyl]ethyl]carbamate | 1609174-44-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 芴
• 英文名称: tert-butyl N-[2-[2-[3-(9H-fluoren-9-ylmethoxycarbonylamino)propanoylamino]ethyldisulfanyl]ethyl]carbamate
• CAS: 1609174-44-8
• 化学式: C₂₇H₃₅N₃O₅S₂
• 分子量: 545.724
• InChiKey: WQBNASRDAMGEMW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  37
• 可旋转键数：
  15
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  156
• 氢给体数：
  3
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  tert-butyl N-[2-[2-[3-(9H-fluoren-9-ylmethoxycarbonylamino)propanoylamino]ethyldisulfanyl]ethyl]carbamate 在 吗啉 作用下， 生成 tert-butyl N-[2-[2-(3-aminopropanoylamino)ethyldisulfanyl]ethyl]carbamate
  参考文献：
  名称：

  [EN] COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC SYNDROME AND DIABETES
  [FR] COMPOSITIONS ET PROCÉDÉS POUR LE TRAITEMENT DU SYNDROME MÉTABOLIQUE ET DU DIABÈTE

  摘要：

  公开号：

  WO2014087307A3
• 作为产物：
  描述：

  FMOC-beta-丙氨酸 、 T-BOC-胱胺 在 N,N-二异丙基乙胺 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 2.5h， 以75%的产率得到tert-butyl N-[2-[2-[3-(9H-fluoren-9-ylmethoxycarbonylamino)propanoylamino]ethyldisulfanyl]ethyl]carbamate
  参考文献：
  名称：

  [EN] COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATION AND METABOLIC DISORDERS
  [FR] COMPOSITIONS ET PROCÉDÉS DE TRAITEMENT D'UNE INFLAMMATION ET DE TROUBLES MÉTABOLIQUES

  摘要：

  公开号：

  WO2014068463A3

文献信息

• [EN] COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC AND LIPID DISORDERS<br/>[FR] COMPOSITIONS ET MÉTHODES POUR LE TRAITEMENT DE TROUBLES MÉTABOLIQUES ET LIPIDIQUES
  申请人：KANDULA MAHESH

  公开号：WO2014083476A2

  公开（公告）日：2014-06-05

  The invention relates to the compounds of formula I and formula II or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I or formula II; and methods for treating or preventing metabolic and lipid disorders may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of diabetes, insulin resistance, hyperglycemia, hypertriglyceridemia, lipid disorders and cardiovascular diseases.
• [EN] COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC SYNDROME AND DIABETES<br/>[FR] COMPOSITIONS ET PROCÉDÉS DE TRAITEMENT DU SYNDROME MÉTABOLIQUE ET DU DIABÈTE
  申请人：KANDULA MAHESH

  公开号：WO2014106804A2

  公开（公告）日：2014-07-10

  The invention relates to the compounds of formula I and formula II or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I or formula II; and methods for treating or preventing metabolic syndrome and diabetes may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of diabetes mellitus, obesity, lipid disorders, neuropathic pain, hypertriglyceridemia, hyperglycemia, hyperinsulinemia and insulin resistance.
• [EN] COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC SYNDROME AND DIABETES<br/>[FR] COMPOSITIONS ET PROCÉDÉS POUR LE TRAITEMENT DU SYNDROME MÉTABOLIQUE ET DU DIABÈTE
  申请人：KANDULA MAHESH

  公开号：WO2014087307A3

  公开（公告）日：2014-07-31
• [EN] COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATION AND METABOLIC DISORDERS<br/>[FR] COMPOSITIONS ET PROCÉDÉS DE TRAITEMENT D'UNE INFLAMMATION ET DE TROUBLES MÉTABOLIQUES
  申请人：KANDULA MAHESH

  公开号：WO2014068463A3

  公开（公告）日：2014-07-31